Selexis, OSE Team Up to Advance Two Cancer Immunotherapy Programs – Immuno-Oncology News
Immuno-Oncology News |
Selexis, OSE Team Up to Advance Two Cancer Immunotherapy Programs
Immuno-Oncology News Selexis and OSE Immunotherapeutics have signed two commercial license agreements (CLAs) to advance the clinical development of two new cancer immunotherapy programs, OSE-172 and OSE-703. The agreement supports the development of OSE's … |
